Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Stem Cell Research

Free Subscription Articles published in Leuk Lymphoma Retrieve available abstracts of 38 articles: HTML format

Single Articles

December 2025
1. HARADA K, Iwata S, Tomita S, Nasukawa M, et al
   Cord blood versus bone marrow/peripheral blood stem cell transplantation under reduced-intensity conditioning in high-risk acute myeloid leukemia and myelodysplastic syndromes.
   Leuk Lymphoma. 2025 Dec 25:1-13. doi: 10.1080/10428194.2025.2604565.
   PubMed     Abstract available
   
   
   
2. SWAROOP A, Oh T, Wolniak K, Sukhanova M, et al
   Donor-derived acute myeloid leukemia after solid organ transplant: evidence for leukemic stem cell transmission.
   Leuk Lymphoma. 2025 Dec 23:1-4. doi: 10.1080/10428194.2025.2604563.
   PubMed    
   
   
   
3. ZHANG T, Cheng X, Jin Y, Zhang R, et al
   Impact of CD34(+) cell infusion dose on immune reconstitution and survival in multiple myeloma after autologous stem cell transplantation.
   Leuk Lymphoma. 2025 Dec 22:1-9. doi: 10.1080/10428194.2025.2604564.
   PubMed     Abstract available
   
   
   
4. CABELLO MODESTO D, McCulloch S, Tay J, Jimenez Zepeda VH, et al
   Autologous stem cell transplantation for the treatment of MGRS (monoclonal gammopathy of renal significance): experience from the University of Calgary.
   Leuk Lymphoma. 2025 Dec 9:1-3. doi: 10.1080/10428194.2025.2598362.
   PubMed    
   
   
   
5. LIN J, He J, Cai Z, He D, et al
   MRD contamination in peripheral blood autologous stem cell grafts: implications for relapse and prognosis in multiple myeloma.
   Leuk Lymphoma. 2025 Dec 4:1-9. doi: 10.1080/10428194.2025.2596804.
   PubMed     Abstract available
   
   
   
6. LIU N, Sun Y, Liu Y, Hu L, et al
   First report of donor-derived active multiple myeloma from one AML patient after allogeneic stem cell transplantation.
   Leuk Lymphoma. 2025 Dec 4:1-5. doi: 10.1080/10428194.2025.2595224.
   PubMed    
   
   
   November 2025
7. SLOGROVE O, Wight J
   Effective management of daratumumab-induced cytopenias with hematopoietic stem cell infusion in relapsed/refractory multiple myeloma: a case report.
   Leuk Lymphoma. 2025 Nov 24:1-4. doi: 10.1080/10428194.2025.2589927.
   PubMed    
   
   
   
8. CHEVILLON F, Dhedin N, Boissel N
   Allogeneic hematopoietic stem cell transplantation in adult with acute lymphoblastic leukemia: evolving indications and modalities in shifting landscape.
   Leuk Lymphoma. 2025 Nov 13:1-13. doi: 10.1080/10428194.2025.2584685.
   PubMed     Abstract available
   
   
   October 2025
9. TAN M, den Elzen N, Goode E, Prabahran A, et al
   Donor-derived somatic genetic rescue with prolonged hematopoietic stability following sibling allogeneic stem cell transplant in SAMD9 syndrome.
   Leuk Lymphoma. 2025 Oct 31:1-4. doi: 10.1080/10428194.2025.2572426.
   PubMed    
   
   
   
10. TOLOSA-RIDAO C, Cid J, Rodriguez-Lobato LG, Charry P, et al
    Endothelial activation and stress index (EASIX) to predict engraftment syndrome after autologous hematopoietic cell transplantation in patients with multiple myeloma. A single center experience.
    Leuk Lymphoma. 2025 Oct 17:1-9. doi: 10.1080/10428194.2025.2556179.
    PubMed     Abstract available
    
    
    
11. DOMINGUEZ-GARCIA JJ, Escamilla MS, Garcia-Avila S, Lopez Pereira B, et al
    Factors associated with long-term quality of life after allogenic stem cell transplantation.
    Leuk Lymphoma. 2025 Oct 10:1-8. doi: 10.1080/10428194.2025.2564769.
    PubMed     Abstract available
    
    
    August 2025
12. CHUMNUMSIRIWATH P, Vittayawacharin P, Pinter-Brown L, Brem EA, et al
    Lite-BEAM expands autologous stem cell transplantation access for older or unfit patients with lymphoma.
    Leuk Lymphoma. 2025 Aug 21:1-5. doi: 10.1080/10428194.2025.2547985.
    PubMed    
    
    
    
13. TOLU SS, Gribbin C, Chen Z, Seshadri MR, et al
    Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents.
    Leuk Lymphoma. 2025 Aug 14:1-11. doi: 10.1080/10428194.2025.2540437.
    PubMed     Abstract available
    
    
    
14. GO AE, Feliciano EJG, Ho FDV, Dee EC, et al
    Hematopoietic stem cell Transplants in the Philippines: barriers to accessibility.
    Leuk Lymphoma. 2025 Aug 9:1-3. doi: 10.1080/10428194.2025.2544076.
    PubMed    
    
    
    July 2025
15. ANDREADIS C, Bobek O, Hsi ED, Fenske TS, et al
    Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup doub
    Leuk Lymphoma. 2025 Jul 9:1-10. doi: 10.1080/10428194.2025.2525982.
    PubMed     Abstract available
    
    
    
16. ODSTRCIL BOBILLO MS, McClune B, Couriel DR
    Access barriers to hematopoietic stem cell transplantation and CAR T-cells in US.
    Leuk Lymphoma. 2025 Jul 6:1-11. doi: 10.1080/10428194.2025.2513003.
    PubMed     Abstract available
    
    
    
17. GULLAKSEN SE, Omsland M, Brevik M, Letzner J, et al
    CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors.
    Leuk Lymphoma. 2025;66:1211-1220.
    PubMed     Abstract available
    
    
    June 2025
18. KOYABU S, Onaka T, Imada K
    Ponatinib may make allogeneic hematopoietic stem cell transplantation unnecessary for CML-BC under specific conditions, such as de novo cases: a case series of de novo CML-BC treated with ponatinib and no transplantation.
    Leuk Lymphoma. 2025 Jun 25:1-4. doi: 10.1080/10428194.2025.2521646.
    PubMed    
    
    
    
19. RATHJE K, Kroger N
    Optimal timing of allogeneic hematopoietic stem cell transplant in MDS.
    Leuk Lymphoma. 2025 Jun 19:1-13. doi: 10.1080/10428194.2025.2514662.
    PubMed     Abstract available
    
    
    
20. MEIRELES AM, Oliveira Rodrigues Amarante ACD, Marques Catita BMC, Abilheira Monjardino MTPB, et al
    Effects of fludarabine dosage on transplant-related outcomes in hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2025 Jun 11:1-5. doi: 10.1080/10428194.2025.2509701.
    PubMed    
    
    
    May 2025
21. THORDARDOTTIR TH, Rodenbach RA, Brauer M, Hall AC, et al
    'A perfect match': how hematologists discuss donor options and risks with black and white patients considering allogeneic stem cell transplant.
    Leuk Lymphoma. 2025 May 7:1-10. doi: 10.1080/10428194.2025.2500625.
    PubMed     Abstract available
    
    
    
22. RAMACHANDRA N, Vegivinti CTR, Sahu S, Sanawar R, et al
    Transforming growth factor beta receptor type I (TGF-betaRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS.
    Leuk Lymphoma. 2025;66:920-929.
    PubMed     Abstract available
    
    
    April 2025
23. GOSHO K, Sadato D, Kato S, Toya T, et al
    Diamond-Blackfan anemia syndrome in an adult with RPS19 and DDX41 variants successfully treated with allogeneic stem cell transplantation: a case report.
    Leuk Lymphoma. 2025 Apr 2:1-4. doi: 10.1080/10428194.2025.2486432.
    PubMed    
    
    
    March 2025
24. BISCHOF L, Ussmann J, Platzbecker U, Jentzsch M, et al
    Allogeneic stem cell transplantation for MDS-clinical issues, choosing preparative regimens and outcome.
    Leuk Lymphoma. 2025 Mar 12:1-14. doi: 10.1080/10428194.2025.2476652.
    PubMed     Abstract available
    
    
    
25. TUCCI A, Re A, Pagani C, Marcheselli L, et al
    A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study.
    Leuk Lymphoma. 2025 Mar 8:1-9. doi: 10.1080/10428194.2025.2471499.
    PubMed     Abstract available
    
    
    February 2025
26. SUN Y, Liu N, Liu Y, Deng J, et al
    Isolated CNS B lymphoid/myeloid bilineage relapse following allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with KMT2A::MLLT1 rearrangement.
    Leuk Lymphoma. 2025 Feb 10:1-4. doi: 10.1080/10428194.2025.2460046.
    PubMed    
    
    
    December 2024
27. SHUMILOV E, Levien L, Mazzeo P, Jung W, et al
    Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning.
    Leuk Lymphoma. 2024 Dec 11:1-12. doi: 10.1080/10428194.2024.2438805.
    PubMed     Abstract available
    
    
    
28. PAISIOU A, OIkonomopoulou C, Pavlidis D, Ampatzidou M, et al
    CDKN2A/B deletion as an independent negative prognostic factor for allogeneic hematopoietic stem cell transplantation in childhood B cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Dec 1:1-4. doi: 10.1080/10428194.2024.2434177.
    PubMed    
    
    
    November 2024
29. LECORNEC N, Duchmann M, Itzykson R
    Single-cell sequencing applications in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Nov 4:1-15. doi: 10.1080/10428194.2024.2422833.
    PubMed     Abstract available
    
    
    October 2024
30. DEHGHANI SS, Wang Y, Ramesh KH, Cooper D, et al
    Atypical chronic myeloid leukemia (CML) with ETV6-ABL1 mutation managed successfully with a third-generation TKI and hematopoietic stem cell transplant.
    Leuk Lymphoma. 2024 Oct 18:1-3. doi: 10.1080/10428194.2024.2403666.
    PubMed    
    
    
    August 2024
31. JEANSELME P, Tavitian S, Lapierre L, Vergez F, et al
    Long-term exposure and response to azacitidine for post-hematopoietic stem cell transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: a case report and review of the literature.
    Leuk Lymphoma. 2024 Aug 14:1-6. doi: 10.1080/10428194.2024.2390572.
    PubMed     Abstract available
    
    
    July 2024
32. DALAL P, Dalal J
    PTCy-ATG mutually exclusive or additive? Anti-thymocyte globulin combined with post-transplantation cyclophosphamide reduce graft-versus-host disease in hematopoietic stem cell transplantation for pediatric leukemia.
    Leuk Lymphoma. 2024 Jul 31:1-2. doi: 10.1080/10428194.2024.2379976.
    PubMed    
    
    
    
33. TARANTINI F, Cumbo C, Anelli L, Zagaria A, et al
    Venetoclax-based treatment in acute myeloid leukemia: an unexpected bonus on the path to allogeneic hematopoietic stem cell transplant?
    Leuk Lymphoma. 2024 Jul 23:1-12. doi: 10.1080/10428194.2024.2381649.
    PubMed     Abstract available
    
    
    
34. HU M, Li J, Hu T, Zhang Z, et al
    Anti-thymocyte globulin combined with post-transplantation cyclophosphamide reduce graft-versus-host disease in hematopoietic stem cell transplantation for pediatric leukemia.
    Leuk Lymphoma. 2024 Jul 7:1-10. doi: 10.1080/10428194.2024.2376179.
    PubMed     Abstract available
    
    
    
35. STEWART C, Owen C, Chua N, Peters A, et al
    Importance of long-term follow-up of autologous stem cell transplantation for mantle cell lymphoma.
    Leuk Lymphoma. 2024 Jul 5:1-4. doi: 10.1080/10428194.2024.2373323.
    PubMed    
    
    
    June 2024
36. JIANG J, Sigmund AM, Zhao Q, Elder P, et al
    Impact of chronic graft-versus-host disease on non-relapse mortality and survival.
    Leuk Lymphoma. 2024 Jun 12:1-8. doi: 10.1080/10428194.2024.2365910.
    PubMed     Abstract available
    
    
    May 2024
37. NAGAYAMA T, Fujiwara SI, Tominaga R, Yokoyama D, et al
    Association of the pre-transplant CD4/CD8 ratio with the prognosis following allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2024 May 20:1-7. doi: 10.1080/10428194.2024.2352614.
    PubMed     Abstract available
    
    
    
38. VON DEM BORNE PA, Kemps-Mols BM, de Wreede LC, van Beek AA, et al
    The degree of HLA matching determines the incidence of cytokine release syndrome and associated nonrelapse mortality in matched related and unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide.
    Leuk Lymphoma. 2024 May 6:1-11. doi: 10.1080/10428194.2024.2344060.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Stem Cell Research is free of charge.